Clinical Trial Update: Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial evaluating G-202 (Mipsagargin) as second-line therapy after sorafenib in advanced hepatocellular carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• G-202 (Mipsagargin) (Mipsagargin)

Snippet

Sponsor: GenSpera, Inc. | Conditions: Advanced Adult Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED